drugset / Trial / NCT00883688
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Phase 2
Completed
24 enrolled
M.D. Anderson Cancer Center
CERN Foundation - Collaborative Ependymoma Research Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of Avastin (bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in pediatric patients. The safety of this drug combination will also be studied.
Timeline
- Start
- 2009-07
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lapatinib | Small molecule | 700 mg/m2 | Oral |